Plasminogen activator inhibitor-1 (PAI-1) inhibitor (IC50
= 3.58 - 60.3 μM). Increases apoptosis in human cancer cell lines. Reduces senescence and increases lifespan in mouse models of ageing (kl/kl). Inhibits L-NAME
(Cat.No. 0665) induced systolic blood pressure increases, telomere length reduction and cardiac hypertrophy in mice. Renoprotective. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice.
Eren M, Boe A, Murphy S, Place A, Nagpal V, Morales-Nebreda L, Urich D, Quaggin S, Budinger G, Mutlu G, Miyata T, Vaughan D
Proc Natl Acad Sci U S A, 2014;111(19):7090-5.
Small molecule inhibitors of plasminogen activator inhibitor-1 elicit anti-tumorigenic and anti-angiogenic activity.
Placencio et al.
PLoS One., 2015;10
Novel plasminogen activator inhibitor-1 inhibitors prevent diabetic kidney injury in a mouse model.
Jeong et al.
PLoS One., 2016;11
Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence.
Boe et al.